Cargando…

Biomarkers for Immune Checkpoint Inhibitors in Melanoma

Immune checkpoint inhibitors have now become a standard therapy for malignant melanoma. However, as immunotherapies are effective in only a limited number of patients, biomarker development remains one of the most important clinical challenges. Biomarkers predicting clinical benefit facilitate appro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitano, Shigehisa, Nakayama, Takayuki, Yamashita, Makiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058029/ https://www.ncbi.nlm.nih.gov/pubmed/30073150 http://dx.doi.org/10.3389/fonc.2018.00270

Ejemplares similares

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

Case Report: A Case of Trimethoprim/Sulfamethoxazole-Triggered Hypotensive Shock: Cytokine Release Syndrome Related to Immune Checkpoint Inhibitors and Drug-Induced Hypersensitivity Syndrome
por: Urasaki, Tetsuya, et al.
Publicado: (2021)

Clinical Development of Immune Checkpoint Inhibitors
por: Ito, Ayumu, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma
por: Katsuya, Yuki, et al.
Publicado: (2023)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
por: Yoshino, Koji, et al.
Publicado: (2019)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma
por: Pan, Chaohu, et al.
Publicado: (2023)

Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2021)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
por: Wang, Ye, et al.
Publicado: (2021)

CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma
por: Zhang, Wengang, et al.
Publicado: (2022)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study
por: Khattak, Muhammad A., et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
por: Lapuente-Santana, Óscar, et al.
Publicado: (2020)

Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
por: Sundar, Raghav, et al.
Publicado: (2020)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

Operative management of immune checkpoint colitis following in-transit melanoma: Case report
por: Childers, Betzaira G., et al.
Publicado: (2023)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Epigenetic Alterations and Biomarkers for Immune Checkpoint Inhibitors–Current Standards and Future Perspectives in Malignant Pleural Mesothelioma Treatment
por: Yoshikawa, Yoshie, et al.
Publicado: (2020)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma
por: Mehdi, Ali, et al.
Publicado: (2020)

Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
por: Kubo, Terufumi, et al.
Publicado: (2021)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence
por: Stonesifer, Connor J., et al.
Publicado: (2021)

Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer
por: Yamashita, Hitomi, et al.
Publicado: (2017)

Liver metastasis affects progression pattern during immune checkpoint inhibitors monotherapy in gastric cancer
por: Motoo, Iori, et al.
Publicado: (2023)

Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Cui, Yanan, et al.
Publicado: (2022)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_36gchehe39ftnre100mbhq4ec6